Subsequently, candidate biomarkers in CSF and serum of MS were validated by enzyme linked immunosorbent assay (ELISA), confirming that CSF and serum’s CHI3L1 CHI3L2 levels were associated with the disease stage (Hinsinger et al., 2015). Here, CHI3L2 is linked to myeloid sarcoma.